How many Maze Therapeutics (MAZE) shares did each Coloma-related trust sell?

The Coloma 2021 Irrevocable Trust sold 116 Maze Therapeutics common shares, and the Coloma Family Trust sold 1,822 shares. Both transactions occurred on May 15, 2026 at a reported price of $26.00 per share in open-market sales.

CEO Coloma trusts trim 1,938 Maze Therapeutics (MAZE) shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Maze Therapeutics, Inc. director and Chief Executive Officer Jason V. Coloma reported open-market sales of common stock executed by family trusts associated with him. On May 15, 2026, The Coloma 2021 Irrevocable Trust sold 116 shares and the Coloma Family Trust sold 1,822 shares, each at $26.00 per share, for a total of 1,938 shares sold.

After these sales, the Coloma Family Trust held 381,073 shares of Maze Therapeutics common stock and The Coloma 2021 Irrevocable Trust held 31,001 shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by Coloma.

Insider Trade Summary 10b5-1

Net Seller: 1,938 shares ($50,388)

Net Sell 2 txns

Insider Coloma Jason V

Role Chief Executive Officer

Sold 1,938 shs ($50K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,822	$26.00	$47K
Sale	Common Stock	116	$26.00	$3K

Holdings After Transaction: Common Stock — 381,073 shares (Indirect, Coloma Family Trust)

Footnotes (1)

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.

Key Figures

Shares sold by Irrevocable Trust: 116 shares at $26.00 Shares sold by Family Trust: 1,822 shares at $26.00 Total shares sold: 1,938 shares +3 more

6 metrics

Shares sold by Irrevocable Trust 116 shares at $26.00 Open-market sale on May 15, 2026

Shares sold by Family Trust 1,822 shares at $26.00 Open-market sale on May 15, 2026

Total shares sold 1,938 shares Aggregate of Coloma-related trust sales

Family Trust holdings after sale 381,073 shares Maze Therapeutics common stock post-transaction

Irrevocable Trust holdings after sale 31,001 shares Maze Therapeutics common stock post-transaction

Rule 10b5-1 plan adoption date February 6, 2026 Covers the reported May 15, 2026 trades

Key Terms

Rule 10b5-1 trading plan, open-market sale, Coloma Family Trust, The Coloma 2021 Irrevocable Trust

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action: "open-market sale" and description: "Sale in open market or private transaction""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Coloma Family Trust financial

"These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees."

The Coloma 2021 Irrevocable Trust financial

"These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees."

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 05:07 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coloma Jason V

(Last)

(First)

(Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/15/2026		S⁽¹⁾		1,822	D	$26	381,073	I	Coloma Family Trust⁽²⁾
Common Stock	05/15/2026		S⁽¹⁾		116	D	$26	31,001	I	The Coloma 2021 Irrevocable Trust⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 6, 2026.

2. These securities are directly held by the Coloma Family Trust (the "Family Trust"), for which the reporting person and his spouse serve as co-trustees.

3. These securities are directly held by The Coloma 2021 Irrevocable Trust (the "Irrevocable Trust"), for which the reporting person and his spouse serve as co-trustees.

Remarks:

The securities reported on this Form 4 as attributable to the Family Trust and the Irrevocable Trust were incorrectly reported on the reporting person's Form 3 as directly held by the reporting person. This Form 4 corrects his Form 3 and restates the attribution of his holdings. All prior Section 16 reports filed on behalf of the reporting person should be understood to incorporate this correction.

	/s/ Courtney Phillips, as attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Maze Therapeutics (MAZE) disclose in this Form 4?

Maze Therapeutics disclosed that family trusts associated with CEO Jason V. Coloma sold 1,938 shares of common stock on May 15, 2026 at $26.00 per share. These were open-market sales executed under a pre-arranged Rule 10b5-1 trading plan.

What are the Coloma trusts’ Maze Therapeutics (MAZE) holdings after the reported sales?

Following the May 15, 2026 transactions, the Coloma Family Trust held 381,073 Maze Therapeutics common shares. The Coloma 2021 Irrevocable Trust held 31,001 common shares. These positions are reported as indirect holdings associated with CEO Jason V. Coloma.

Was the Maze Therapeutics (MAZE) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by Jason V. Coloma on February 6, 2026. Such plans allow pre-scheduled trading, reducing the role of day-to-day discretion in timing.

Who is the reporting person in this Maze Therapeutics (MAZE) Form 4 filing?

The reporting person is Jason V. Coloma, who serves as both a director and Chief Executive Officer of Maze Therapeutics. The reported sales involve shares held indirectly through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.